Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01026467 · ClinicalTrials.gov registry record
Frailty Index and Geriatric Assessment in Predicting Toxicity to Front-Line Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer
A clinical trial, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- 45
- Enrollment target
NCT01026467: Completed study, sponsored by Wake Forest University Health Sciences.
NCT01026467 is a clinical trial that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 45 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01026467 has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- 45 participants
- Enrollment target
Study Summary
This phase II trial is studying how well a frailty index and geriatric assessment works in predicting toxicity to front-line chemotherapy in treating patients with stage IV non-small cell lung cancer. A frailty index and geriatric assessment prior to treatment may help identify a better treatment regimen
Interventions
- DRUG cisplatin
- DRUG carboplatin
- OTHER questionnaire administration
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2010-01 |
| Est. Completion | 2014-05 |
What the finished NCT01026467 record still lists
NCT01026467 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 45 participants, a relatively small participant target.
The record links to 0 conditions, and to 3 interventions - of which cisplatin is the first listed.
NCT01026467 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01026467 about?
NCT01026467 is a clinical study titled "Frailty Index and Geriatric Assessment in Predicting Toxicity to Front-Line Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer". This phase II trial is studying how well a frailty index and geriatric assessment works in predicting toxicity to front-line chemotherapy in treating patients with stage IV non-small cell lung cancer. A frailty index and geriatric assessment prior to treatment may help identify a better treatment re...
What is the current status of trial NCT01026467?
This trial is currently completed. The enrollment target is 45 participants. The study started on 2010-01. Estimated completion is 2014-05.
What interventions are being tested in trial NCT01026467?
The interventions under investigation include: cisplatin (DRUG), carboplatin (DRUG), questionnaire administration (OTHER).
Who is sponsoring clinical trial NCT01026467?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia